Literature DB >> 31072902

Draft Genome Sequence of a Rare Israeli Clinical Isolate of Burkholderia pseudomallei.

Ofir Israeli1, Inbar Cohen-Gihon1, Tal Brosh-Nissimov2,3, Anat Zvi1, Adi Beth-Din1, Ohad Shifman1, Ma'ayan Israeli1, Uri Elia1, Shirley Lazar1, Erez Bar-Haim1, Ofer Cohen1, Theodor Chitlaru4.   

Abstract

We report here the draft genome sequence of Burkholderia pseudomallei MAA2018. This highly virulent strain was isolated in 2018 from the first melioidosis case in Israel associated with recreational travel to Goa, India.
Copyright © 2019 Israeli et al.

Entities:  

Year:  2019        PMID: 31072902      PMCID: PMC6509527          DOI: 10.1128/MRA.00281-19

Source DB:  PubMed          Journal:  Microbiol Resour Announc        ISSN: 2576-098X


ANNOUNCEMENT

The Gram-negative bacterium Burkholderia pseudomallei is the etiological cause of melioidosis, a severe zoonotic infectious disease (165,000 global estimated annual morbidities, including 89,000 deaths [1]) that is endemic mainly in Southeast Asia and northern Australia (2). B. pseudomallei is considered a potential bioweapon (CDC category B) due to the prevalence in soil and water, multiple routes of infection, and especially high virulence associated with inhalation exposure, low infectious dose, high mortality rates, native resistance to a wide range of antibiotics, and nonavailability of a vaccine (3, 4). Melioidosis is manifested by nonspecific symptoms that hinder identification of the disease and consequently may inadvertently be diagnosed as tuberculosis or a common form of pneumonia (1, 5, 6). The B. pseudomallei genome, consisting of two chromosomes, is highly plastic, resulting in a high number of strains exhibiting significant variability in genetic features (7). We report here the draft genome sequence of a clinical B. pseudomallei strain isolated from a melioidosis case diagnosed in Israel and associated with recreational travel to Goa, India. This is the third documented clinical isolate of melioidosis in Israel (8, 9) and the first case originating from India. The isolate, referred to as B. pseudomallei MAA2018 (melioidosis case from Assuta Hospital, Ashdod, Israel, in 2018) was isolated from sputum collected from a 29-year-old male returning from Goa, India, suffering from a subacute upper-lobe pneumonia of a 6-month duration. The identification of the infectious agent as B. pseudomallei was initially suggested by a metabolism-specific bacterial identification system (Vitek XL2) and matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) spectrum (Vitek mass spectrometer [MS]) and subsequently confirmed by PCR analysis, as described previously (10). Virulence analysis of B. pseudomallei MAA2018 in the murine model of melioidosis established an intranasal 50% lethal dose (LD50; determined by following for 30 days the survival of mice inoculated with increasing doses of bacteria and calculated by linear regression using the GraphPad Prism version 5 statistical analysis software [described in references 11 and 12]) of 6 CFU and 30 CFU in the BALB/c and C57BL/6J strains of mice, respectively, suggesting that it belongs to a group of highly virulent B. pseudomallei strains (13). For the genome sequencing of B. pseudomallei MAA2018, DNA was extracted from a 40-h-old colony grown on Luria broth (LB) agar using the QIAamp DNA blood minikit (Qiagen). A Nextera XT paired-end library (Illumina) was prepared from 1 ng DNA. The library was sequenced on a MiSeq platform (Illumina) using paired-end sequencing with 150 nucleotides (nt) and a mean insertion size of 503 nt. This produced 5,148,334 reads, with 130 coverage (length of the reads × read number/genome length) mapping to B. pseudomallei. For Nanopore sequencing, libraries were prepared from 5 ng of genomic DNA (gDNA) using a rapid PCR barcoding kit (SQK-RPB004; Oxford Nanopore), without fragmentation, and sequenced on the MinION using a MK1 R9.4 flow cell, following the protocol for 1D genomic gDNA, producing 16,809 reads. A hybrid Nanopore-Illumina de novo assembly was determined using SPAdes (14), with the following parameters: -t 4 –m 32 –k 31, 51, 71. The number of assembled contigs larger than 1,000 nt was 183. The N50 contig size was 80,391 nt. FastQC was used to check the raw sequence data for quality control (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The draft genome of the MAA2018 strain consisted of 7,423,108 bp (G+C content, 67%). The genomic sequence of the MAA2018 isolate was compared to B. pseudomallei genomes available in the NCBI database, revealing that it differs from its most closely related strain, B. pseudomallei 2008724758 (GenBank accession number CP018382), a clinical isolate collected in 2010 in California from a melioidosis case with unknown travel history (15), by 8,708 and 8,166 single-nucleotide polymorphisms (SNPs) on chromosomes 1 and 2, respectively.

Data availability.

This whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession numbers SLUE01000001 to SLUE01000183 (BioProject number PRJNA525961 and BioSample number SAMN11081001). The raw reads were submitted and are available in the Sequence Read Archive at the NCBI as Fast5 files (SRA accession number PRJNA525961).
  15 in total

1.  Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei.

Authors:  Matthew T G Holden; Richard W Titball; Sharon J Peacock; Ana M Cerdeño-Tárraga; Timothy Atkins; Lisa C Crossman; Tyrone Pitt; Carol Churcher; Karen Mungall; Stephen D Bentley; Mohammed Sebaihia; Nicholas R Thomson; Nathalie Bason; Ifor R Beacham; Karen Brooks; Katherine A Brown; Nat F Brown; Greg L Challis; Inna Cherevach; Tracy Chillingworth; Ann Cronin; Ben Crossett; Paul Davis; David DeShazer; Theresa Feltwell; Audrey Fraser; Zahra Hance; Heidi Hauser; Simon Holroyd; Kay Jagels; Karen E Keith; Mark Maddison; Sharon Moule; Claire Price; Michael A Quail; Ester Rabbinowitsch; Kim Rutherford; Mandy Sanders; Mark Simmonds; Sirirurg Songsivilai; Kim Stevens; Sarinna Tumapa; Monkgol Vesaratchavest; Sally Whitehead; Corin Yeats; Bart G Barrell; Petra C F Oyston; Julian Parkhill
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-17       Impact factor: 11.205

2.  SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing.

Authors:  Anton Bankevich; Sergey Nurk; Dmitry Antipov; Alexey A Gurevich; Mikhail Dvorkin; Alexander S Kulikov; Valery M Lesin; Sergey I Nikolenko; Son Pham; Andrey D Prjibelski; Alexey V Pyshkin; Alexander V Sirotkin; Nikolay Vyahhi; Glenn Tesler; Max A Alekseyev; Pavel A Pevzner
Journal:  J Comput Biol       Date:  2012-04-16       Impact factor: 1.479

Review 3.  Burkholderia mallei and Burkholderia pseudomallei as bioterrorism agents: national aspects of emergency preparedness.

Authors:  Jacob Gilad; Idit Harary; Tsvika Dushnitsky; David Schwartz; Yoram Amsalem
Journal:  Isr Med Assoc J       Date:  2007-07       Impact factor: 0.892

Review 4.  Melioidosis; the remarkable imitator: recent perspectives.

Authors:  Rama Chaudhry; Benu Dhawan
Journal:  J Assoc Physicians India       Date:  2004-05

5.  Development and validation of Burkholderia pseudomallei-specific real-time PCR assays for clinical, environmental or forensic detection applications.

Authors:  Erin P Price; Julia L Dale; James M Cook; Derek S Sarovich; Meagan L Seymour; Jennifer L Ginther; Emily L Kaufman; Stephen M Beckstrom-Sternberg; Mark Mayo; Mirjam Kaestli; Mindy B Glass; Jay E Gee; Vanaporn Wuthiekanun; Jeffrey M Warner; Anthony Baker; Jeffrey T Foster; Patrick Tan; Apichai Tuanyok; Direk Limmathurotsakul; Sharon J Peacock; Bart J Currie; David M Wagner; Paul Keim; Talima Pearson
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

6.  Evaluation of surrogate animal models of melioidosis.

Authors:  Jonathan Mark Warawa
Journal:  Front Microbiol       Date:  2010-12-29       Impact factor: 5.640

7.  Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain.

Authors:  Theodor Chitlaru; Ma'ayan Israeli; Erez Bar-Haim; Uri Elia; Shahar Rotem; Sharon Ehrlich; Ofer Cohen; Avigdor Shafferman
Journal:  Sci Rep       Date:  2016-01-06       Impact factor: 4.379

8.  Imported melioidosis, Israel, 2008.

Authors:  Avivit Cahn; Benjamin Koslowsky; Ran Nir-Paz; Violeta Temper; Nurit Hiller; Alla Karlinsky; Itzhak Gur; Carlos Hidalgo-Grass; Samuel N Heyman; Allon E Moses; Colin Block
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

9.  Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis.

Authors:  Direk Limmathurotsakul; Nick Golding; David A B Dance; Jane P Messina; David M Pigott; Catherine L Moyes; Dionne B Rolim; Eric Bertherat; Nicholas P J Day; Sharon J Peacock; Simon I Hay
Journal:  Nat Microbiol       Date:  2016-01-11       Impact factor: 17.745

10.  Clinical features and laboratory diagnosis of infection with the potential bioterrorism agents burkholderia mallei and burkholderia pseudomallei.

Authors:  Jacob Gilad; David Schwartz; Yoram Amsalem
Journal:  Int J Biomed Sci       Date:  2007-09
View more
  1 in total

1.  Case Report: Imported Melioidosis from Goa, India to Israel, 2018.

Authors:  Tal Brosh-Nissimov; Daniel Grupel; Shlomi Abuhasira; Hanna Leskes; Ma'ayan Israeli; Shirley Lazar; Uri Elia; Ofir Israeli; Adi Beth-Din; Erez Bar-Haim; Inbar Cohen-Gihon; Anat Zvi; Ofer Cohen; Theodor Chitlaru
Journal:  Am J Trop Med Hyg       Date:  2019-09       Impact factor: 2.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.